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Background. Due to the unintended potential misclassifications of the World Health Organization (WHO) immunological fail-
ure criteria in predicting virological failure, limited availability of treatment options, poor laboratory infrastructure, and healthcare
providers’ confidence in making switches, physicians delay switching patients to second-line antiretroviral therapy (ART). Evaluating
whether timely switching and delayed switching are associated with the risk of opportunistic infections (OI) among patients with
unrecognized treatment failure is critical to improve patient outcomes.
Methods. A retrospective review of 637 adolescents and adults meeting WHO immunological failure criteria was conducted.
Timely and delayed switching to second-line ART were defined when switching happened at <3 and ≥3 months, respectively,
after failure diagnosis was made. Cox proportional hazard marginal structural models were used to assess the effect of switching
to second-line ART on the risk of developing OI.
Results. Of 637 patients meeting WHO immunological failure criteria, 396 (62.2%) switched to second-line ART. Of those
switched, 230 (58.1%) were delayed. Switching to second-line ART reduced the risk of OI (adjusted hazards ratio [AHR], 0.4;
95% CI, .2–.6). Compared with patients who received timely switch after failure diagnosis was made, those who delayed switching
were more likely to develop OI (AHR, 2.2; 95% CI, 1.1–4.3).
Conclusions. Delayed switching to second-line ART after failure diagnosis may increase the risk of OI. Serial immunological
assessment for switching patients to second-line ART is critical to improve their outcomes.
Keywords. HIV; immunological failure; opportunistic infection; second-line ART; switching.
Diagnosis and treatment of patients failing first-line antiretroviral
therapy (ART) in low- and middle-income countries (LMIC) re-
mains challenging [1, 2]. Because of the lack of routine viral load
monitoring, the definition of treatment failure to a large extent de-
pends entirely onWorld Health Organization (WHO) clinical and
immunological failure criteria [3–5].Due to the potential misclas-
sification of treatment failure resulting from using these failure
criteria [6–9] as well as limited availability of treatment options,
poor laboratory infrastructure, low healthcare provider confidence
in making switches, and high costs of second-line ART, physicians
are often reluctant [3, 4, 10, 11] to switch. One consequence of
unrecognized treatment failures and/or delayed switches may be
an increased risk of opportunistic infections (OI).
Delayed switching to second-line ART in programs without
routine viral load monitoring is common. A higher proportion
of patients remain on a failed first-line regimen in programs
without routine viral load monitoring, compared with those
in programs with routine viral load monitoring [8]. Of patients
meeting WHO immunological and clinical failure criteria,
<45% are switched to second-line ART [12, 13]. The rate of
switch is higher in eastern Europe than in sub-Saharan Africa
[14], and the difference in the rates of switch is attributed to
the lack of routine viral load monitoring in African programs.
A delay in switching is also indicated by the variation in switch-
ing times from diagnosis of failure [2, 14]. In addition, in
resource-limited settings, switching happens earlier in programs
with routine viral load monitoring than in those without [15].
Despite treatment success for many patients on second-line
ART, mortality and virological failure rates are high [14, 16–19].
Virological failure is defined as increasing levels of detectable
human immunodeficiency virus (HIV) RNA and is associated
with multiple nucleoside/nucleotide resistance mutations
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[20, 21]. Higher levels of HIV RNA pose the risk of OI. Other
than medication nonadherence, high mortality and treatment
failure may also be due to delayed switching among patients
with unrecognized treatment failure. Compared with patients
meeting clinical/immunological failure criteria and switched
into second-line ART, those who met criteria and did not
switch had poor survival [13].
Reports about the frequency of OI among patients failing
first-line ART in LMIC are limited. Whether disproportionally
higher OI are observed in patients remaining on failed first-line
regimen compared with those who switched to second-line
ART is not understood. We sought to evaluate the influence
of switching and delayed switching to second-line ART on
the risk of OI among patients meeting immunological failure
criteria.
METHODS
Study Design and Population
We used a retrospective cohort study design to evaluate the
effect of switching to second-line ART on the incidence of OI
among patients infected with HIV in Northern Tanzania. Re-
cords of patients attending the Kilimanjaro Christian Medical
Centre (KCMC), Mawenzi Regional Hospital (MRH), and
Kibosho, Kilema, and Machame Hospitals between January
2004 and August 2013 were reviewed. Patients who were <13
years old were excluded. According to the hierarchy of the
health system in Tanzania, KCMC is a tertiary referral hospital,
MRH is a regional hospital, and Kibosho, Kilema, and Ma-
chame are district hospitals. These care and treatment centers
(CTCs) offer treatment according to the Tanzanian Ministry
of Health treatment guidelines for the provision of ART. Ac-
cording to these guidelines, patients receive a fixed-dose combi-
nation of stavudine (D4T), lamivudine (3TC), and nevirapine
(NVP) as first-line ART. Zidovudine (AZT) and efavirenz re
used in place of D4T and NVP, respectively, depending upon
toxicities and concurrent medications. Each patient is
typically seen on a monthly basis and their prescriptions are re-
filled. At the time of this study, routine viral load monitoring
was not available in these CTCs; therefore, patients were
switched to second-line ART based on clinical and immunolog-
ical criteria according to the WHO guidelines (www.who.int/
hiv/pub/arv/adult2010) of a decline in CD4+ cell count to the
pretreatment value or below ≥50% decline from the peak value
CD4+ cell count value while on treatment or persistent low CD4+
cell count <100 c/mm3. The drugs used for second-line ART
included tenofovir, abacavir (ABC), and lopinavir/ritonavir
(LPV/r); atazanavir/ritonavir was substituted for LPV/r as need-
ed. The second-line nucleoside reverse-transcriptase inhibitor
choice for adolescents and adults depended on the first-line
ART. For patients on AZT or D4T in first-line ART, the default
second-line option was tenofovir disoproxil fumarate (TDF)
combined with 3TC or FTC and LPV/r. For those who had
received TDF in first-line, the second-line option was an AZT-
based regimen. For those who were on TDF during first-line
because of intolerance to AZT or D4T, an alternative second-
line option was ABC combined with 3TC or FTC and LPV/r.
Data Collection
As part of routine HIV clinical care, all patient data including
demographics, medication use, OI, adherence indicators
(adherent = fewer than 2 missed days per month/nonadherent = 2
or more missed days per month), and laboratory values were
collected on standardized forms and entered into a database
designed and funded by the Tanzanian National AIDS Control
Program in collaboration with Elizabeth Glaser Pediatric AIDS
Foundation. This database was searched for clinical data, and
when information was missing, it was abstracted from their
respective medical files. Treatment monitoring included clinical
and immunological criteria; CD4+ cell counts were checked at
4- to 6-month intervals using flow cytometry.
Definition of Variables
The primary end point was the time from immunological failure
to the first occurrence of OI (pulmonary tuberculosis [TB], pneu-
monia, Kaposi’s sarcoma [KS], cryptococcal meningitis [CM],
and herpes zoster [HZ]). All TB, KS, CM, and some pneumonia
infections were confirmed by the laboratory, histopathology,
or x-ray, whereas HZ infections were diagnosed clinically. We
defined loss to follow-up as the absence of a documented clinic
visit 6 months from date of the previous clinic visit.
The exposure of interest was time until switching to second-
line ART. We defined switching to second-line as initiation of
a boosted protease inhibitor-based regimen; otherwise, the
patient was considered not switched. Furthermore, among
those switched to second-line, we defined timely switching
and delayed switching as switching occurring at <3 months vs
≥3 months after the diagnosis of immunological failure was
made, respectively. A cutoff of 3 months was chosen because
after a failure diagnosis, patients received 1 to 2 months of
intensive adherence counseling before making the switch.
Institutional review board approval was obtained from the
University of North Carolina and KCMC.
Statistical Analyses
Statistical analyses were conducted using Statistical Analysis
Software (SAS), version 9.3 (SAS Institute Inc., Cary, NC).
The distribution of continuous variables was explored to
guide categorization. Frequencies and distributions of sociode-
mographic and clinical characteristics were computed.
Because switching to second-line ART is influenced by CD4+
cell counts, confounding by indication is a potential problem
such that patients with low CD4+ cell are more likely to be
switched to second-line than those without low CD4+ cell.
Time-varying covariate (CD4 cell) affects both time-varying ex-
posure (time to switching) and outcome (OI or death). In addi-
tion, switching history predicts future CD4 cell count. Because
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of the existence of such scenarios, the use of marginal structural
models (MSMs) is recommended. We assessed the effect of
switching to second-line ART on the risk of OI using Cox pro-
portional hazards MSMs, which address confounding by indi-
cation. CD4+ cell count was considered as a time-varying
confounder. To ensure switching to second-line ART happened
after a time-varying confounder, CD4+ cell count values at fail-
ure diagnosis were assigned to the preceding month. Other
covariates included age, gender, adherence to first-line ART, ad-
herence to second-line ART, treatment sites, and duration spent
on first-line ART. Patients began accumulating person time
from the moment failure diagnosis was made, and they were
observed until first occurrence of an opportunistic infection,
death, lost to follow-up, or end of the study, whichever came
first. All patients who died, were loss to follow-up, and did
not experience OI were censored in the primary analysis.
Marginal structural model analyses use inverse probability of
exposure weights to control confounding by time-varying
covariates that are also on the causal pathway from exposure to
outcome. In this case, the persons were assigned weights in-
versely proportional to their probability of having the exposure,
given their exposure and covariate histories. We used logistic
regression models to compute the weights, and all weights were
stabilized. After computation of the stabilized weights, we used
Cox proportional hazards MSMs to estimate the associations.
All associations were presented as adjusted hazard ratios
(AHRs) with 95% confidence intervals (CIs). Estimates whose
CIs excluded 1 were regarded as statistically significant.
Kaplan–Meier curves were used to assess the survival distri-
butions among those who were switched and those who were
not switched to second-line ART. We used log-rank tests to
compare the hazard functions for those switched against
those not switched to second-line ART. Poisson regression
models were used to compute the incidence rate of OI. Two
sensitivity analyses were performed: the first defined time from
failure diagnosis to death or first occurrence of OI used as the
outcome, and the second used propensity scores weighting to as-
sess the effect of switching to second-line ART on the risk of OI.
In the second case, the main exposure switching to second-line
ART was considered as time fixed mimicking the design of
a randomized controlled trial where every eligible patient
would be assigned either to be switched or not at baseline. A re-
gression model to generate the scores included the following
variables: age (<30, 30–55, >55), gender, months patient spent
on first-line ART (<36, 36–60, >60), CD4 cell count (<100,
100–200, >200), sites (tertiary hospital, regional hospital, district
hospital), percentage adherence to first-line ART (<90, ≥90), and
percentage adherence to second-line ART (<90, ≥90).
RESULTS
From January 2004 through August 2013, we identified 637 ad-
olescent and adult patients at the 5 sites who met WHO
immunological failure criteria. Three hundred ninety-four
(61.8%) patients were female, and the majority (454, 71.3%)
of patients were aged between 30 and 55 years (Table 1).
Most patients (476, 74.7%) had suboptimal adherence to first-
line ART, 360 (56.5%) patients spent <36 months on first-line
ART, and 174 (43.9%) patients had CD4+ cell count of <100/
mm3 at the time of switching to second-line ART. Three hun-
dred ninety-six (62.2%) patients switched to second-line ART,
whereas 241 (37.8%) patients did not. Among those switched,
233 (58.8%) switched within the first 3 months from the time
failure diagnosis was made.
Approximately one fifth (n = 115; 18.1%) experienced an op-
portunistic infection. The most common infections were pneumo-
nia (n = 46; 7.2%) and TB (n = 35; 5.5%). Other OI included CM,
KS, or HZ (n = 34; 5.3%).
Table 1. Demographic and Clinical Characteristics of HIV-Infected
Adolescents and Adults Meeting WHO Immunologic Failure Criteria at 5











Male 243 (38.2) 146 (36.9) 97 (40.2)
Female 394 (61.8) 250 (63.1) 144 (59.8)
Age
<30 y 134 (21.0) 97 (24.5) 37 (15.3)
30–55 y 454 (71.3) 221 (68.4) 123 (75.9)
>55 y 49 (7.7) 28 (7.1) 21 (8.7)
Duration on first-line ART
<36 mo 360 (56.5) 222 (56.1) 138 (57.3)
36–60 mo 187 (29.4) 146 (31.8) 61 (25.3)
>60 mo 90 (14.1) 28 (12.1) 32 (17.4)
First-line adherence
Optimal 161 (25.3) 98 (24.8) 63 (26.1)
Suboptimal 476 (74.7) 298 (75.2) 178 (73.9)
Second-line adherencea
Optimal N/A 260 (65.7) N/A
Suboptimal N/A 136 (34.3) N/A
CD4 cells at time of switcha
<100 c/mm³ N/A 174 (43.9) N/A
100–200 c/mm³ N/A 166 (41.9) N/A
>200 c/mm³ N/A 56 (14.1) N/A
Sites
Tertiary hospital 327 (51.3) 244 (61.6) 83 (34.5)
Regional Hospital 167 (26.2) 92 (23.2) 75 (31.1)
District Hospital 143 (22.5) 60 (15.2) 83 (34.4)
Infectionsa
Tuberculosis 35 (5.5) 14 (3.5) 21 (8.7)
Pneumonias 46 (7.2) 12 (3.0) 34 (14.1)
Meningitis 1 (0.2) 0 (0.0) 1 (0.4)
Kaposis sarcoma 8 (1.3) 3 (0.8) 5 (2.1)
Herpes zoster 25 (3.9) 9 (2.3) 16 (6.6)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; N/A, not
applicable; WHO, World Health Organization.
a Not measured in full 637.
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Survival Distributions Among Those Switched and Those not Switched
to Second-Line Antiretroviral Therapy
During the follow-up, 637 patients contributed 1181 person-
years with overall median of follow up of 1.4 (interquartile
range [IQR], 0.7–2.7) years. Those who switched had a median
follow up of 2.3 (IQR, 1.2–3.9) years, the corresponding median
follow up among those who did not switch was 1.0 (IQR,
0.5–1.4) years. Among those who switched, 38 experienced an
opportunistic infection (incidence rate = 5.4 per 100 person-
years [95% CI, 4.0–7.5]), compared with 77 among those who
did not switch (incidence rate = 15.9 per 100 person-years [95%
CI, 12.7–19.9]) The difference in probabilities of developing OI
among those switched and those who did not switch is apparent
from the start of follow up (Figure 1). Kaplan–Meier curves
showed a steep decline of OI free-survival during the first 16
months among patients not switched to second-line. The 6-
and 12-month probabilities of having OI among those switched
to second-line ART were 0.03 and 0.07, respectively, compared
with 0.13 and 0.36 among those who did not switch (P < .001,
log-rank test).
Compared with patients who met immunological failure cri-
teria and did not switch to second-line ART, those who met and
switched were less likely to acquire OI (AHR, 0.4; 95% CI, .2–.6;
Table 2). The models were adjusted for age, gender, duration on
first-line ART, site of care, and adherence.
Among those switched to second line ART, compared with
patients who were timely switched after their failure diagnosis
was made, those who were delayed to switch were more
likely to acquire OI (AHR, 2.2; 95% CI, 1.1–4.3; Table 3).
When the primary end point was defined as death or occur-
rence of the first opportunistic infection, compared with
patients who met immunological failure criteria and did not
switch to second-line ART, those who met and switched were
less likely to die or acquire OI (AHR, 0.4; 95% CI, .2–.7;
Table 4).
The logistic regression model used to estimate the propensity
score yielded a c-statistic of 0.8. The mean propensity to receive
second-line ART was 0.7 (standard deviation, 0.2) compared
with 0.4 (standard deviation, 0.2) for those who did not receive
second-line ART. The distribution of the propensity score for
those switched to second-line ART was somewhat higher than
those who did not switch to second-line; however, approximate-
ly 97.7% of the propensity scores overlapped between the
2 groups. Using propensity scores analyses, compared with
patients who met immunological failure criteria and did not
switch to second-line ART, those who met and switched were
less likely to acquire OI (AHR, 0.2; 95% CI, .1–.2; Table 5).
DISCUSSION
The study attempted to assess the association between switching
to second-line ART and the risk of OI among HIV-infected pa-
tients meeting immunologic failure criteria from 5 CTCs in
northern Tanzania. We demonstrated that switching to sec-
ond-line ART reduced the incidence of OI among patients
meeting immunological failure criteria infections (AHR, 0.4;
Figure 1. Kaplan–Meier curves for 637 human immunodeficiency virus-infected
adolescent and adult patients according to switching status.
Table 2. Risk Factors of Opportunistic Infections Among HIV-Infected
Adolescents and Adults Switched and Those not Switched Into Second-
Line Antiretroviral Therapy at 5 Infectious Disease Clinics in Kilimanjaro











No 77 483.3 15.9 1
Yes 38 697.3 5.4 0.4 (.2–.6)b
Gender
Male 43 489.1 8.8 1
Female 72 691.5 10.4 1.2 (.8–1.7)
Age
<30 y 27 270.4 10.0 1
30–55 y 80 827.0 9.7 0.9 (.5–1.5)
>55 y 8 83.2 9.6 0.6 (.3–1.5)
Duration on first-line ART
<36 mo 76 647.4 11.7 1
36–60 mo 29 371.2 7.8 0.5 (.3–.8)b
>60 mo 10 161.9 6.2 0.3 (.1–.6)b
First-line adherence
Optimal 20 357.2 5.6 1
Suboptimal 95 823.4 11.5 1.5 (.9–2.4)
Second-line adherence
Optimal 43 686.3 6.2 1
Suboptimal 72 494.3 14.6 1.3 (.8–1.9)
Sites
Tertiary Hospital 54 738.3 7.3 1
Regional Hospital 30 251.8 11.9 1.1 (.7–1.8)
District Hospital 31 190.4 16.3 1.3 (.8–2.1)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human
immunodeficiency virus; HR, hazards ratio; py, person years.
a Hazards ratios are based on analysis of Cox proportional marginal structural models on 636
patients.
b Statistically significant.
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95% CI, .2–.6). Furthermore, time of switching impacted the
risk of OI with longer delays associated with approximately 2-
fold increase in risk relative to timely switching.
In the absence of routine viral load testing for determining
treatment failure, delayed switching is common in many low-
and middle-income countries [2, 14, 19]. In this study, only
62% of those meeting immunological failure criteria switched
at all, and the median time to switch from the time of immuno-
logical failure diagnosis was 5.1 months. Limited availability of
the second-line medications, low sensitivity of theWHO immu-
nologic failure criteria in predicting virological failure, and low
confidence of healthcare providers in making switches may
have contributed to the delays in switching. In addition to
these factors, delays in switching in this cohort could as also
be explained by the low levels of adherence. Approximately
75% of the patients had adherence levels below 90% before
switch. Those with low levels of adherence may have been less
likely to be switched. Similar delays in switching were docu-
mented in Haiti where the median time to switching to
second-line ART was 7 months and patients with adherence
below 90% were less likely to be switched [13]. Substantial pro-
portions of patients who met immunological failure criteria in a
study from Mali [3] did not switch to second-line ART, and the
median duration of follow up from failure diagnosis was 5
months. These observations suggest that delays in switching
to second-line ART are a serious management concern across
low- and middle-income countries.
Among patients meeting immunological failure criteria,
switching to second-line ART is associated with a 60% reduc-
tion in the risk of OI compared with those who remained on
a failed first-line regimen. The association between immunolog-
ical failure and the incidence of HZ has been reported previous-
ly [22], in which the incidence of HZ was 6.2 episodes per 100
person years. We observed a slightly lower incidence rate of 2.1
episodes per 100 person years. The high incidence of OI is likely
attributable to unrecognized treatment failure and relatively
severe immunosuppression. Among those who switched,
approximately half of the patients in our study had CD4+ cell
count <100 c/mm3 at the time of switch. Severe immunosup-
pression defined by CD4+ cell <100 c/mm3 is a clear risk factor
for OI such as TB and pneumonia [23, 24].
Our sensitivity analyses results were robust with the results
from the main analysis. Using propensity scores, switching to
second-line ART is associated with an 80% reduction in the
risk of OI compared with those who remained on a failed
Table 3. Risk Factors of Opportunistic Infections Among HIV-Infected
Adolescents and Adults Switched Into Second-Line Antiretroviral












Yes 11 323.1 3.4 1
No 27 374.2 7.2 2.2 (1.1–4.3)b
Gender
Male 15 277.6 5.4 1
Female 23 419.6 5.5 1.1 (.5–2.1)
Age
<30 y 12 177.3 6.8 1
30–55 y 22 486.2 4.5 0.5 (.2–1.3)
>55 y 4 33.8 11.8 1.6 (.2–4.8)
Duration on first-line ART
<36 mo 22 445.7 4.9 1
36–60 mo 11 211.7 5.2 1.0 (.3–3.6)
>60 mo 5 39.9 12.5 1.5 (.5–4.3)
First-line adherence
Optimal 4 219.4 1.8 1
Suboptimal 34 477.9 7.1 4.1 (1.4–12.6)b
Second-line adherence
Optimal 23 510.7 4.5 1
Suboptimal 15 186.6 8.0 1.7 (.6–5.2)
Sites
Tertiary Hospital 22 516.7 4.3 1
Regional Hospital 11 120.2 9.2 1.5 (.7–3.6)
District Hospital 5 60.4 8.3 1.5 (.5–4.5)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human
immunodeficiency virus; HR, hazards ratio; py, person years.
a Hazards ratios are based on analysis of Cox proportional marginal structural models on 396
switched to second line ART.
b Statistically significant.
Table 4. Analyses of the Effect of Switching to Second Line Antiretroviral
Therapy on Risk of Opportunistic Infections or Deaths Among HIV-Infected
Adolescents and Adults at 5 Infectious Disease Clinics in Kilimanjaro











No 77 697.3 4.6 1
Yes 48 483.3 3.3 0.4 (.2–.7)b
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazards
ratio; py, person years.
a Hazards ratios are based on analysis of Cox proportional marginal structural models on 396
patients.
b Statistically significant.
Table 5. Propensity Score Analyses of the Effect of Switching to Second-
Line Antiretroviral Therapy on Risk of Opportunistic Infections Among HIV-
Infected Adolescents and Adults at 5 Infectious Disease Clinics in
Kilimanjaro Region, Moshi, Tanzania 2004–2013
Variable Categories AHR 95% CI
Switched No 1
Yes 0.2 (.1–.2)a
Abbreviations: AHR, adjusted hazard ratio; CI, confidence interval; HIV, human
immunodeficiency virus.
a Statistically significant.
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first-line regimen. The mean propensity among those switched
to second line ART was higher than that of those who did not
switch, indicating that those switched were at a greater need to
receive second-line ART than those who did not.
Combining deaths and OI as the end point, the effect of
switching to second-line persisted; the risk of death or OI was
less among those switched compared with those continued on
the failed first-line regimen. Among those who died, 31% had
OI before death. Others have previously shown that delayed
switching is associated with an increased risk of mortality [13,
25]. Although the causes of death were not ascertained in these
studies, it is likely patients had life-threatening OI before their
deaths.
Many of the OI in this study were clinically diagnosed. Mis-
diagnosis might have overestimated the incidence of OI. Al-
though it is possible to misdiagnose pneumonia infections
clinically, the dermatological manifestations of HZ are obvious
and unlikely to be misdiagnosed in patients infected with HIV.
Moreover, clinical diagnosis of HZ is common in many studies
[22, 26, 27]. Although TB infections were confirmed by sputum
examination, the presence of smear negative does not rule out
TB, especially in patients infected with HIV. The timing of
sputum collection and processing can also impact the diagnosis
of TB. Variations in timing and processing from different
laboratories might have underestimated the incidence of TB
infections.
The timing of diagnosis of OI could be measured with some
errors in this study. Due to the factors related to patients, access
to care, and healthcare systems in LMIC, diagnoses of TB and
KS and other acquired immune deficiency syndrome-defining
cancers are likely to be made late [28, 29]. All patients in this
study were screened for TB at ART initiation, and patients
were periodically evaluated for TB as they attended their
CTCs. In addition, with monthly clinic visits and periodic eval-
uation, errors in the timing of diagnosis of OI are likely to be
minimal.
Because CD4+ cell counts were measured at intervals of 4–6
months, the diagnosis of treatment failure was made late in
most patients, especially those whose CD4+ cells were measured
at 6-month intervals. In our analyses, the most current CD4+
cell measurements were assigned to the previous month to
account for possible late treatment failure diagnosis.
We did not have HIV-RNA results for the patients, and there-
fore CD4 cell count were used to make failure diagnosis. It is like-
ly that some patients considered failed might not have failed and
those with virological failure might have not been included into
the study. Such misclassification of the failure diagnosis might
have introduced selection bias. Moreover, practically, HIV
RNA is known to influence both OI and physicians’ decision
in making switches. However, because physicians did not have
the knowledge of the HIV-RNA results, it is unlikely that their
decisions were directly influenced by the HIV RNA. High plasma
HIV-RNA leads to suppression of the patient’s immunity, which
is being reflected by the low CD4 cell count that was controlled
for in this study.
We compared switched versus not switched and timely
switched versus delayed switched separately; however, compar-
ison of not switched versus timely switched and delayed
switched in a single model is another alternative. Moreover,
death could be a competing risk in a model assessing effects
of switching and risk of OI or death, and therefore the resultant
effect size could be biased. Furthermore, because patients who
failed in 2004 would be much less likely to access second-line
treatment than those in 2013, inclusion of the year of immuno-
logical failure in the estimation of the propensity score proba-
bilities would have slightly changed propensity score effects size.
CONCLUSIONS
The risk of OI and death is reduced among patients switched to
second-line ART after a diagnosis of immunological failure is
made. Furthermore, the risk of opportunistic infection is higher
when the delay to switch is 3 months or longer from the time of
failure. Delay in switching could mainly be due to uncertainties
physicians have due to the relatively poor ability of the WHO
immunological failure criteria to predict virological failure. If
this theory is true, efforts should be made to invest in viral
load testing equipment to improve the timing of failure diagno-
sis and manage patients accordingly. This process could be
made possible by placing a central testing laboratory where pa-
tients’ dry blood spots from different care and treatment centers
could be evaluated. Dry blood spot is known to reduce logistic
difficulties and the cost that is associated with the use of plasma.
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